Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA)

被引:37
作者
Bassetti, M
Di Biagio, A
Cenderello, G
Del Bono, V
Palermo, A
Cruciani, M
Bassetti, D
机构
[1] Univ Genoa, Osped San Martino, Sch Med, Dept Infect Dis, I-16132 Genoa, Italy
[2] Univ Genoa, Osped San Martino, Sch Med, Dept Orthopaed, I-16132 Genoa, Italy
[3] Borgo Trento Hosp, Dept Infect Dis, Verona, Italy
关键词
D O I
10.1053/jinf.2001.0863
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Prosthetic joint infection is an infrequent but serious complication of total joint arthroplasty. Complete removal of all foreign material is essential. however when prosthesis removal is not possible or contra indicated, suppressive antibiotic therapy with retention of the functioning hip arthroplasty may be considered. Linezolid. the first approved oxazolidinone. appears to be a promising new agent for the treatment of serious Gram-positive infections. We report two cases of Methicillin-resistant Staphylococcus aureus (MRSA) prosthetic hip infections successfully treated with a long course of linezolid. This observation suggest that linezolid is a promising drug for the treatment of prosthetic joint infections due to MRSA or other Gram-positive pathogens, particularly when other therapeutic approaches are not feasible or a long-term antibiotic therapy, is required. (C) 2001 The British Infection Society.
引用
收藏
页码:148 / 149
页数:2
相关论文
共 10 条
[1]   Total hip arthroplasty: Use and select complications in the US Medicare population [J].
Baron, JA ;
Barrett, J ;
Katz, JN ;
Liang, MH .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1996, 86 (01) :70-72
[2]   Staphylococcus aureus prosthetic joint infection treated with prosthesis removal and delayed reimplantation arthroplasty [J].
Brandt, CM ;
Duffy, MCT ;
Berbari, EF ;
Hanssen, AD ;
Steckelberg, JM ;
Osmon, DR .
MAYO CLINIC PROCEEDINGS, 1999, 74 (06) :553-558
[3]  
BRAUSE BD, 2000, PRINCIPLES PRACTICE, P1196
[4]   Linezolid [J].
Clemett, D ;
Markham, A .
DRUGS, 2000, 59 (04) :815-827
[5]  
EFTEKHAR NS, 1986, CLIN ORTHOP RELAT R, P65
[6]   CURRENT CONCEPTS REVIEW INFECTION AFTER TOTAL HIP-ARTHROPLASTY PAST, PRESENT, AND FUTURE [J].
GARVIN, KL ;
HANSSEN, AD .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1995, 77 (10) :1576-1588
[7]   Linezolid and reversible myelosuppression [J].
Green, SL ;
Maddox, LC ;
Huttenbach, ED .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (10) :1291-1291
[8]  
Marcou G, 1997, INT I ADM SCI MONOGR, V5, P11
[9]  
Moellering RC, 1998, CLIN INFECT DIS, V26, P1177, DOI 10.1086/520288
[10]   In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents [J].
Zurenko, GE ;
Yagi, BH ;
Schaadt, RD ;
Allison, JW ;
Kilburn, JO ;
Glickman, SE ;
Hutchinson, DK ;
Barbachyn, MR ;
Brickner, SJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) :839-845